Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (294)
- COVID-19 (164)
- Safety monitoring and information (121)
- Compliance and enforcement (101)
- Legislation (80)
- Manufacturing (60)
- Vaping hub (59)
- Labelling and packaging (46)
- Import and export (41)
- Medicinal cannabis hub (28)
- Scheduling (national classification system) (28)
- Sunscreens (21)
- Weight loss products (18)
- Shortages and supply disruptions (10)
- Committees and advisory bodies (9)
- Cosmetics (6)
- Clinical trials (5)
- Unique Device Identification (UDI) hub (5)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1309 result(s) found, displaying 1076 to 1100
-
BlogFood and medicine have different roles in our health, and must follow different regulations.
-
Media releasesJuice Plus Company Australia Pty Ltd has paid penalties of $37,800 for alleged advertising breaches relating to vitamin products
-
Media releasesInSkin Cosmedics Group Pty Ltd has paid penalties of $37,800 in regards to the alleged supply and advertising of the Dermapen 4
-
BlogIn a bushfire or other natural disaster you might need emergency access to an important medicine. Here are some tips on how to plan ahead.
-
BlogThis Australia Day, we celebrate some Australian innovators in therapeutic goods.
-
Media releasesMeasles vaccine testing shows the vaccine meets required standards
-
News articlesThe Health Products Regulation Group has published a new regulatory science strategy
-
Media releasesPharmacies and others can advertise availability of OTC salbutamol products during the bushfire season
-
Regulatory decision noticesOn 20 November 2019 the TGA issued a direction notice to Cat Media concerning its advertising of Fatblaster Clinical
-
BlogAbuse of human growth hormone can cause permanent health issues.
-
Media releasesMundipharma Pty Ltd has paid penalties of $302,400 in response to 24 infringement notices issued by the TGA
-
-
Regulatory decision noticesA new S41BD(3) instrument has been signed to declare that some nappy rash products are not to be medical devices for the purposes of the Act
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
-
News articlesSome label warnings no longer required for medicines containing very low concentrations of menthol or methyl salicylate
-
Regulatory decision noticesNew requirements for listed medicines containing Andrographis paniculata
-
Media releasesWe will closely consider the judgement including any further improvements that could enhance the regulatory system in Australia.
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
Media releasesAcalabrutinib receives approval through the second international collaborative review initiative between the TGA, FDA and Health Canada
-
Media releasesThe TGA has joined the ICMRA and the WHO in a coordinated global approach to fighting antimicrobial resistance
-
Media releasesConsumer Healthcare Products Australia to handle all medicine advertising pre-approval applications
-
BlogFrom animals intestines to intrauterine devices, contraception has a fascinating history.
-
News articlesGeneral information for consumers on prescription opioids
-